Abstract
Numerous studies have investigated the potential use of TNF-related apoptosis-inducing ligand (TRAIL) as a cancer therapeutic since its discovery in 1995 – because TRAIL is a potent inducer of apoptosis in tumor cells but not in normal cells and tissues. Consequently, a great deal is known about TRAIL/TRAIL receptor expression, the molecular components of TRAIL receptor signaling, and methods of altering tumor cell sensitivity to TRAIL-induced apoptosis. Our laboratory was the first to report the possibility of TRAIL gene transfer therapy as an alternative method of using TRAIL as an antitumor therapy. As with recombinant proteins administered systemically, intratumoral TRAIL gene delivery also has limitations that can restrict its full potential. Translating the preclinical TRAIL studies into the clinic has started, with the hope that TRAIL will exhibit robust tumoricidal activity against human primary tumors in situ with minimal toxic side effects.
Keywords: TRAIL, apoptosis, tumor, adenovirus, immunotherapy
Current Gene Therapy
Title: TRAIL Gene Therapy: From Preclinical Development to Clinical Application
Volume: 9 Issue: 1
Author(s): Thomas S. Griffith, Brittany Stokes, Tamara A. Kucaba, James K. Earel Jr., Rebecca L. VanOosten, Erik L. Brincks and Lyse A. Norian
Affiliation:
Keywords: TRAIL, apoptosis, tumor, adenovirus, immunotherapy
Abstract: Numerous studies have investigated the potential use of TNF-related apoptosis-inducing ligand (TRAIL) as a cancer therapeutic since its discovery in 1995 – because TRAIL is a potent inducer of apoptosis in tumor cells but not in normal cells and tissues. Consequently, a great deal is known about TRAIL/TRAIL receptor expression, the molecular components of TRAIL receptor signaling, and methods of altering tumor cell sensitivity to TRAIL-induced apoptosis. Our laboratory was the first to report the possibility of TRAIL gene transfer therapy as an alternative method of using TRAIL as an antitumor therapy. As with recombinant proteins administered systemically, intratumoral TRAIL gene delivery also has limitations that can restrict its full potential. Translating the preclinical TRAIL studies into the clinic has started, with the hope that TRAIL will exhibit robust tumoricidal activity against human primary tumors in situ with minimal toxic side effects.
Export Options
About this article
Cite this article as:
Griffith S. Thomas, Stokes Brittany, Kucaba A. Tamara, Earel Jr. K. James, VanOosten L. Rebecca, Brincks L. Erik and Norian A. Lyse, TRAIL Gene Therapy: From Preclinical Development to Clinical Application, Current Gene Therapy 2009; 9 (1) . https://dx.doi.org/10.2174/156652309787354612
DOI https://dx.doi.org/10.2174/156652309787354612 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Type I Interferons: Ancient Peptides with Still Under-Discovered Anti-Cancer Properties
Protein & Peptide Letters Targeting the BH3 Domain of Bcl-2 Family Proteins. A Brief History From Natural Products to Foldamers As Promising Cancer Therapeutic Avenues
Current Medicinal Chemistry Inhibition of Hyaluronan Synthase-3 Decreases Subcutaneous Colon Cancer Growth by Increasing Apoptosis
Anti-Cancer Agents in Medicinal Chemistry Cancer Therapy: Targeting Cell Cycle Regulators
Anti-Cancer Agents in Medicinal Chemistry Pharmacological Activation of p53 in Cancer Cells
Current Pharmaceutical Design ABCC6 as a Target in Pseudoxanthoma Elasticum
Current Drug Targets Inhibition of Hedgehog/Gli Signaling by Botanicals: A Review of Compounds with Potential Hedgehog Pathway Inhibitory Activities
Current Cancer Drug Targets Emerging Insight into MAPK Inhibitors and Immunotherapy in Colorectal Cancer
Current Medicinal Chemistry Clinical Use of Therapies Targeting Tumor Vasculature and Stroma
Current Cancer Drug Targets Therapeutic Targeting of G-Protein Coupled Receptor-Mediated Epidermal Growth Factor Receptor Transactivation in Human Glioma Brain Tumors
Mini-Reviews in Medicinal Chemistry Targeting Telomerase for Cancer Therapy
Current Cancer Therapy Reviews Gene Therapy and Targeted Toxins for Glioma
Current Gene Therapy Better Antiretroviral Central Nervous System Penetration is Not Associated with Reduced Chronic Pain in People Living with Human Immunodeficiency Virus
Anti-Infective Agents The Influence of Macrophages and the Tumor Microenvironment on Natural Killer Cells
Current Molecular Medicine Cyclin-Dependent Kinase as a Novel Therapeutic Target: An Endless Story
Current Chemical Biology Immune Stimulatory Strategies for the Prevention and Treatment of Asthma
Current Pharmaceutical Design Immunobiology of Herpes Simplex Virus and Cytomegalovirus Infections of the Fetus and Newborn
Current Immunology Reviews (Discontinued) Src Kinase Inhibitors: An Update on Patented Compounds
Current Medicinal Chemistry Diaryl Urea: A Privileged Structure in Anticancer Agents
Current Medicinal Chemistry Therapeutic Implications of Tocilizumab, A Humanized Anti-Interleukin-6 Receptor Antibody, for Various Immune-Mediated Diseases: An Update Review
Current Rheumatology Reviews